Clinical Trial Detail

NCT ID NCT03024996
Title A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

clear cell renal cell carcinoma

renal cell carcinoma

sarcomatoid renal cell carcinoma

Therapies

Atezolizumab

Age Groups: adult senior

No variant requirements are available.